PHYSICIANS: Activity|Indications|Safety Information|Dosing|Suprax FAQ's|Patient Education
PATIENTS|SALES INFORMATION
Suprax® is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms1
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Proven efficacy | |||||||||||||||||||||||||
In otitis media: | |||||||||||||||||||||||||
Bacteriologic outcome of otitis media at 2 to 4 weeks post-therapy: 81% efficacy in pediatric patients with otitis media in US NDA trials with Suprax® 8 mg/kg QD (N=387)1 | |||||||||||||||||||||||||
In a recent clinical study in otitis media (N=313), Suprax® at 8 mg/kg QD provided efficacy comparable to that of amoxicillin/clavulanic acid at 40 mg/kg TID2 | |||||||||||||||||||||||||
In uncomplicated urinary tract infections: |
|||||||||||||||||||||||||
In a study of adults with complicated or uncomplicated UTI (n=60), 99% of patients were cured or improved after treatment with Suprax® 400 mg tablets for 3 to 7 days1 | |||||||||||||||||||||||||
In a study of children aged 6 months to 13 years (n=38) treated with Suprax®, clinical success was noted in 100% of patients after the first 72 hours of treatment2 | |||||||||||||||||||||||||
In uncomplicated gonorrhea: |
|||||||||||||||||||||||||
The only oral antibiotic recommended by the CDC | |||||||||||||||||||||||||
For the treatment of uncomplicated urogenital and anorectal gonorrhea, the CDC recommends ceftriaxone 125 mg (single intramuscular injection) or Suprax® 400 mg (single oral dose)3 | |||||||||||||||||||||||||
References: 1. Ludwig E. Cefixime in the treatment of respiratory or urinary tract infections. Chemotherapy. 1998;44(suppl 1):31-34. 2. Dagan R, Einhorn M, Lang R, et al. Once daily cefixime compared with twice daily trimethoprim/sulfamethoxazole for treatment of urinary tract infections in infants and children. Pediatr Infect Dis J. 1992;11:198-203. 3. Centers for Disease Control and Prevention. Update to CDC’s Sexually Transmitted Disease Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR. 2007;56:332-336. | |||||||||||||||||||||||||
Please view Package insert for more information about side effects and safe use of Suprax® | |||||||||||||||||||||||||